Wockhardt Ltd announced that a leading UK medical journal published a case study on a U.S. liver transplant patient successfully treated with their antibiotic Zaynich (WCK 5222) for a severe pan-drug resistant infection. This announcement was made under Regulation 30 of SEBI on July 28, 2025.